Immunotherapy Combination Selection Is Driven by PD-L1 in Gastroesophageal Cancer | OncLive
Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy...
onclive.com